JAK3 and primary cutaneous T-cell non-Hodgkin lymphoma: Tofacitinib has been shown to inhibit JAK3 in CTCL [45] but other JAK inhibitors such as momelotinib, baricitinib or filgotinib have not been tested in TCL.